BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the 44^th Annual J.P. Morgan Healthcare Conference.

Management will present from 9:45am to 10:25am Pacific Time on Monday, January 12^th, 2026.

A live and archived webcast will be available on the “Events & Presentations” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/news-events/events-presentations.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Investor Contact
ir@billiontoone.com

Media Contact
billiontoone@moxiegrouppr.com